CCL

Összesen 4 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM009099
Első szerző:Czifra Gabriella (élettanász)
Cím:Increased expressions of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate carcinoma / Czifra, G., Varga, A., Nyeste, K., Marincsak, R., Toth, B. I., Kovacs, I., Kovacs, L., Biro, T.
Dátum:2009
ISSN:0171-5216
Megjegyzések:Recently, functional cannabinoid receptor-1 (CB1) and vanilloid receptor-1 (TRPV1) have been described in human prostate and prostate cancer-derived cell lines where the activation of the receptors resulted in inhibition of cellular growth. We, however, lack the description of the expression of these molecules in human prostate cancer (PCC) and in benign prostate hyperplasia (BPH). METHODS: Therefore, immunohistochemistry, Western blotting, and quantitative "real-time Q-PCR were performed to define the expressions of CB1 and TRPV1 in healthy and diseased prostate tissues. RESULTS: CB1 was identified in epithelial and smooth muscle cells types of the human prostate, whereas TRPV1 was exclusively localized to the mucosal cells. We also found that the expression of CB1 and TRPV1 (both at the protein and mRNA levels) were significantly up-regulated in PCC. However, while the increased expression of TRPV1 showed a proper correlation with increasing PCC tumor grades, such phenomenon was not observed with CB1. In addition, we also measured markedly elevated CB1 levels in BPH tissues whilst the expression of TRPV1 was not altered when compared to healthy control prostate. CONCLUSIONS: Our findings strongly argue for that (1) the CB1 and TRPV1 molecules as well as their ligands may indeed possess a promising future role in the treatment of PCC; (2) TRPV1 may also serve as a prognostic factor in PCC; and (3) CB1 may act as a potential target molecule in the therapeutic management of BPH.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Journal of Cancer Research and Clinical Oncology. - 135 : 4 (2009), p. 507-514. -
További szerzők:Varga Attila (1949-) (urológus, andrológus) Nyeste Katalin Marincsák Rita (1979-) (fogszakorvos) Tóth István Balázs (1978-) (élettanász) Kovács Ilona (1965-) (patológus) Kovács László (1939-) (élettanász) Bíró Tamás (1968-) (élettanász)
Internet cím:DOI
elektronikus változat
elektronikus változat
Borító:

2.

001-es BibID:BIBFORM016031
Első szerző:Lázár József
Cím:Sensitization of recombinant vanilloid receptor-1 by various neurotrophic factors / József Lázár, Tamás Szabó, Rita Marincsák, László Kovács, Peter M. Blumberg, Tamás Bíró
Dátum:2004
ISSN:0024-3205
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
Megjelenés:Life Sciences. - 75 : 2 (2004), p. 153-163. -
További szerzők:Szabó Tamás (1968-) (gyermekgyógyász) Marincsák Rita (1979-) (fogszakorvos) Kovács László (1939-) (élettanász) Blumberg, Peter M. Bíró Tamás (1968-) (élettanász)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

3.

001-es BibID:BIBFORM009104
Első szerző:Marincsák Rita (fogszakorvos)
Cím:Increased expression of TRPV1 in squamous cell carcinoma of the human tongue / Marincsak, R., Toth, B. I., Czifra, G., Marton, I., Redl, P., Tar, I., Toth, L., Kovacs, L., Biro, T.
Dátum:2009
ISSN:1354-523X
Megjegyzések:Recent reports have unambiguously identified the presence and the growth-modulatory role of transient receptor potential vanilloid-1 (TRPV1), a central integrator of pain sensation, on numerous non-neuronal cell types and, of great importance, in certain malignancies. In this study, we have investigated the molecular expression of TRPV1 in the human tongue and its high-incidence malignant (squamous cell carcinoma, SCC) and premalignant (leukoplakia) conditions. Methods: Immunohistochemistry, Western blotting and quantitative 'real-time' Q-PCR were performed to define the expression of TRPV1. Results: A weak and sparse TRPV1-specific immunoreactivity was identified in the basal layers of the healthy human tongue epithelium. By contrast, we observed a dramatically elevated TRPV1-immunoreactivity in all layers of the epithelium both in precancerous and malignant samples. Furthermore, statistical analysis revealed that the marked overexpression of TRPV1 found in all grades of SCC showed no correlation with the degree of malignancy of the tumours. Finally, the molecular expression of TRPV1 was also identified in an SCC-derived cell line and was shown to be increased in parallel with the accelerated growth of the cells. Conclusion: Collectively, our findings identify TRPV1 as a novel, promising target molecule in the supportive treatment and diagnosis of human tongue SCC.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Oral Diseases. - 15 : 5 (2009), p. 328-335. -
További szerzők:Tóth István Balázs (1978-) (élettanász) Czifra Gabriella (1975-) (élettanász) Márton Ildikó (1954-) (fogszakorvos) Redl Pál (1953-) (szájsebész) Tar Ildikó (1967-) (fogszakorvos) Tóth László (1971-) (patológus) Kovács László (1939-) (élettanász) Bíró Tamás (1968-) (élettanász)
Internet cím:DOI
elektronikus változat
elektronikus változat
Borító:

4.

001-es BibID:BIBFORM004104
Első szerző:Marincsák Rita (fogszakorvos)
Cím:The analgesic drug, tramadol, acts as an agonist of the transient receptor potential vanilloid-1 / Marincsák R., Tóth B.I., Czifra G., Szabó T., Kovács L., Bíró T.
Dátum:2008
Megjegyzések:Tramadol is an effective analgesic substance widely used in medical practice. Its therapeutic action have been mainly attributed to the activation of mu-opioid receptors as well as to the inhibition of neurotransmitter reuptake mechanisms and various voltage- and ligand-gated ion channels of the nociceptive system. As transient receptor potential vanilloid-1 (TRPV1, "the capsaicin receptor") has been shown to function as a central integrator molecule of pain sensation, our aim in the current study was to define the involvement of TRPV1 in the complex mechanism of action of tramadol. METHODS: To achieve these goals, we used single-cell Ca-imaging as well as fluorescent image plate reader assays on Chinese hamster ovary (CHO) cells heterologously over-expressing TRPV1. RESULTS: We found that (1) tramadol, similar to the well-known TRPV1 agonist, capsaicin, significantly increased [Ca(2+)](i) of TRPV1-CHO cells in a concentration-dependent fashion; (2) its effect was reversibly prevented by the TRPV1 antagonist capsazepine; (3) repeated application of tramadol resulted in marked tachyphylaxis; and (4) tramadol did not modify [Ca(2+)](i) in control (empty vector expressing) CHO cells. CONCLUSIONS: Collectively, these findings strongly support the intriguing and novel concept that tramadol acts as an agonist of TRPV1. Considering that activation of TRPV1 on sensory neurons is followed by a local release of vasoactive neuropeptides and a marked desensitization of the afferent fibers (hence termination of pain sensation), our findings may equally explain both the desired analgesic as well as the often-seen, yet "unexpected," local side effects (e.g., initiation of burning pain and erythema) of tramadol.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Anesthesia and Analgesia. - 106 : 6 (2008), p. 1890-1896. -
További szerzők:Tóth István Balázs (1978-) (élettanász) Czifra Gabriella (1975-) (élettanász) Szabó Tamás (1968-) (gyermekgyógyász) Kovács László (1939-) (élettanász) Bíró Tamás (1968-) (élettanász)
Internet cím:elektronikus változat
elektronikus változat
DOI
Borító:
Rekordok letöltése1